NZ541098A - Method for production of the R,R (or S,S) configuration of glycopyrronium stereoisomers - Google Patents
Method for production of the R,R (or S,S) configuration of glycopyrronium stereoisomersInfo
- Publication number
- NZ541098A NZ541098A NZ541098A NZ54109803A NZ541098A NZ 541098 A NZ541098 A NZ 541098A NZ 541098 A NZ541098 A NZ 541098A NZ 54109803 A NZ54109803 A NZ 54109803A NZ 541098 A NZ541098 A NZ 541098A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- diastereomeric mixture
- solvent
- diastereomeric
- isomers
- Prior art date
Links
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical class C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 23
- 238000000034 method Methods 0.000 claims abstract description 54
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 74
- 239000002904 solvent Substances 0.000 claims description 61
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 46
- 238000001953 recrystallisation Methods 0.000 claims description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 238000005956 quaternization reaction Methods 0.000 claims description 29
- 229960002462 glycopyrronium bromide Drugs 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- -1 2-cyclopentyl-2-hydroxy-2-phenylacetyl Chemical group 0.000 claims description 21
- 238000002425 crystallisation Methods 0.000 claims description 21
- 230000008025 crystallization Effects 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000002244 precipitate Substances 0.000 claims description 18
- 238000005809 transesterification reaction Methods 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 8
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 2
- ANGKOCUUWGHLCE-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-UHFFFAOYSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 239000011343 solid material Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 208000004998 Abdominal Pain Diseases 0.000 abstract description 2
- 208000002881 Colic Diseases 0.000 abstract description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract description 2
- 206010029148 Nephrolithiasis Diseases 0.000 abstract description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract description 2
- 230000001022 anti-muscarinic effect Effects 0.000 abstract description 2
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 208000035475 disorder Diseases 0.000 abstract description 2
- 208000001130 gallstones Diseases 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 239000003149 muscarinic antagonist Substances 0.000 abstract description 2
- 230000000414 obstructive effect Effects 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 230000002921 anti-spasmodic effect Effects 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 16
- 238000000926 separation method Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 7
- 238000004611 spectroscopical analysis Methods 0.000 description 7
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229940102396 methyl bromide Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- FLVFPAIGVBQGET-RXMQYKEDSA-N (3r)-1-methylpyrrolidin-3-ol Chemical compound CN1CC[C@@H](O)C1 FLVFPAIGVBQGET-RXMQYKEDSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229940015042 glycopyrrolate Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FLVFPAIGVBQGET-YFKPBYRVSA-N (3s)-1-methylpyrrolidin-3-ol Chemical compound CN1CC[C@H](O)C1 FLVFPAIGVBQGET-YFKPBYRVSA-N 0.000 description 1
- FLVFPAIGVBQGET-UHFFFAOYSA-N 1-methylpyrrolidin-3-ol Chemical compound CN1CCC(O)C1 FLVFPAIGVBQGET-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- FGMUSNHTKNGVQD-AWEZNQCLSA-N methyl (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1([C@](O)(C(=O)OC)C=2C=CC=CC=2)CCCC1 FGMUSNHTKNGVQD-AWEZNQCLSA-N 0.000 description 1
- FGMUSNHTKNGVQD-CQSZACIVSA-N methyl (2s)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1([C@@](O)(C(=O)OC)C=2C=CC=CC=2)CCCC1 FGMUSNHTKNGVQD-CQSZACIVSA-N 0.000 description 1
- FGMUSNHTKNGVQD-UHFFFAOYSA-N methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C=1C=CC=CC=1C(O)(C(=O)OC)C1CCCC1 FGMUSNHTKNGVQD-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0189602A AT412088B (de) | 2002-12-18 | 2002-12-18 | Verfahren zur herstellung der r,r oder s,s konfigurierten glycopyrronium-isomere |
| PCT/EP2003/014432 WO2004054971A1 (de) | 2002-12-18 | 2003-12-18 | Verfaren zur herstellung des r,r (oder s,s) konfugurierten glycopyrronium-stereoisomers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ541098A true NZ541098A (en) | 2008-08-29 |
Family
ID=31192804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ541098A NZ541098A (en) | 2002-12-18 | 2003-12-18 | Method for production of the R,R (or S,S) configuration of glycopyrronium stereoisomers |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7569598B2 (enExample) |
| EP (1) | EP1572641B1 (enExample) |
| JP (1) | JP2007524565A (enExample) |
| CN (1) | CN100349867C (enExample) |
| AT (2) | AT412088B (enExample) |
| AU (1) | AU2003290075B2 (enExample) |
| CA (1) | CA2510280C (enExample) |
| DK (1) | DK1572641T3 (enExample) |
| ES (1) | ES2383799T3 (enExample) |
| NO (1) | NO330851B1 (enExample) |
| NZ (1) | NZ541098A (enExample) |
| PL (1) | PL214802B1 (enExample) |
| PT (1) | PT1572641E (enExample) |
| RU (1) | RU2337096C2 (enExample) |
| WO (1) | WO2004054971A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0504463D0 (en) | 2005-03-03 | 2005-04-13 | Arakis Ltd | Method of crystallisation and purification |
| JP5902612B2 (ja) * | 2009-04-09 | 2016-04-13 | ノバルティス アーゲー | ピロリジニウム塩の調製方法 |
| WO2011157387A1 (en) * | 2010-06-14 | 2011-12-22 | Chiesi Farmaceutici S.P.A. | Crystal form of glycopyrronium chloride |
| CN103159659A (zh) * | 2011-12-19 | 2013-06-19 | 沈阳药科大学 | 一种毒蕈碱受体拮抗剂格隆溴铵的制备方法 |
| DK2607351T3 (en) * | 2011-12-22 | 2017-06-06 | Cerbios-Pharma S A | CONTINUOUS PROCEDURE FOR ALKYLICATION OF CYCLIC TERTIARY AMINES |
| CN102627595A (zh) * | 2012-03-09 | 2012-08-08 | 徐奎 | 一种制备格隆溴铵的方法 |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| KR20150119468A (ko) | 2013-02-28 | 2015-10-23 | 더미라, 인코포레이티드 | 글리코피롤레이트 염 |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
| CN104586841A (zh) * | 2013-10-30 | 2015-05-06 | 中国药科大学 | (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途 |
| CN107304178B (zh) * | 2016-04-21 | 2020-03-27 | 辽宁药联制药有限公司 | 一种毒蕈碱受体拮抗剂格隆溴铵手性对映体的制备方法 |
| CN107345945B (zh) * | 2016-05-05 | 2019-12-17 | 辽宁药联制药有限公司 | 一种拆分格隆溴铵对映体及杂质检查的高效液相色谱方法 |
| CN113234003B (zh) * | 2021-04-23 | 2024-02-02 | 广东嘉博制药有限公司 | 一种格隆溴铵及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ336202A (en) * | 1996-11-11 | 2000-10-27 | Christian R Noe | Pure enantiomer aryl-cycloalkyl-hydroxycarboxylic acid esters and use in treating smooth muscle spasms and respiritory diseases |
-
2002
- 2002-12-18 AT AT0189602A patent/AT412088B/de not_active IP Right Cessation
-
2003
- 2003-12-18 CA CA2510280A patent/CA2510280C/en not_active Expired - Fee Related
- 2003-12-18 EP EP03782435A patent/EP1572641B1/de not_active Expired - Lifetime
- 2003-12-18 RU RU2005122497/04A patent/RU2337096C2/ru active
- 2003-12-18 AU AU2003290075A patent/AU2003290075B2/en not_active Ceased
- 2003-12-18 CN CNB2003801098187A patent/CN100349867C/zh not_active Expired - Fee Related
- 2003-12-18 WO PCT/EP2003/014432 patent/WO2004054971A1/de not_active Ceased
- 2003-12-18 US US10/540,187 patent/US7569598B2/en not_active Expired - Lifetime
- 2003-12-18 NZ NZ541098A patent/NZ541098A/en not_active IP Right Cessation
- 2003-12-18 DK DK03782435.6T patent/DK1572641T3/da active
- 2003-12-18 PT PT03782435T patent/PT1572641E/pt unknown
- 2003-12-18 PL PL377441A patent/PL214802B1/pl unknown
- 2003-12-18 AT AT03782435T patent/ATE548348T1/de active
- 2003-12-18 JP JP2004560470A patent/JP2007524565A/ja active Pending
- 2003-12-18 ES ES03782435T patent/ES2383799T3/es not_active Expired - Lifetime
-
2005
- 2005-07-15 NO NO20053473A patent/NO330851B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2337096C2 (ru) | 2008-10-27 |
| CN100349867C (zh) | 2007-11-21 |
| ATA18962002A (de) | 2004-02-15 |
| PL214802B1 (pl) | 2013-09-30 |
| PT1572641E (pt) | 2012-06-15 |
| US20060167275A1 (en) | 2006-07-27 |
| ES2383799T3 (es) | 2012-06-26 |
| AT412088B (de) | 2004-09-27 |
| EP1572641B1 (de) | 2012-03-07 |
| JP2007524565A (ja) | 2007-08-30 |
| WO2004054971A1 (de) | 2004-07-01 |
| NO330851B1 (no) | 2011-08-01 |
| CA2510280C (en) | 2011-09-27 |
| CN1751022A (zh) | 2006-03-22 |
| AU2003290075B2 (en) | 2009-01-29 |
| EP1572641A1 (de) | 2005-09-14 |
| PL377441A1 (pl) | 2006-02-06 |
| AU2003290075A1 (en) | 2004-07-09 |
| CA2510280A1 (en) | 2004-07-01 |
| US7569598B2 (en) | 2009-08-04 |
| NO20053473L (no) | 2005-09-19 |
| ATE548348T1 (de) | 2012-03-15 |
| DK1572641T3 (da) | 2012-07-02 |
| RU2005122497A (ru) | 2006-01-20 |
| NO20053473D0 (no) | 2005-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2407135T3 (es) | Uso de (3S,2'R)-glicopirronio como medicamento | |
| AU2003290075B2 (en) | Method for production of the r,r (or s,s) configuration of glycopyrronium stereoisomers | |
| EA005528B1 (ru) | Тартраты 5,8,14-триазатетрацикло[10.3.1.02,11.04,9]гексадека-2(11),3,5,7,9-пентаена | |
| WO2005037783A2 (fr) | Composes tricycliques comme inhibiteurs de transport de glycine | |
| EP0486386A2 (fr) | Nouveaux dérivés de la N-benzoyl proline, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| US11584715B2 (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| FR2546166A1 (fr) | Enantiomeres du erythro (benzyl-4 piperidino)-2 (hydroxy-4 ou benzyloxy-4 phenyl)-1 propanol, leur preparation et leur application en therapeutique | |
| JP7307282B2 (ja) | ベンゾ２－アザスピロ［４．４］ノナン系化合物及びその使用 | |
| CN112739686B (zh) | 用于制备(-)-西苯唑啉琥珀酸盐的新方法 | |
| JPH01186866A (ja) | 分割化アミノピロリジン神経防護剤 | |
| JP2006528201A (ja) | 塩酸レバルブテロールの製造 | |
| JP2002516896A (ja) | Ｒ−（−）−カルニチンの立体選択的合成のための化学的方法 | |
| CA2284976C (en) | Process for preparing single enantiomer narwedine | |
| US20240239791A1 (en) | Processes for the synthesis of valbenazine | |
| FR2610322A1 (fr) | Nouveaux derives de la pilocarpine, leur preparation et leur utilisation comme medicaments | |
| US20090082436A1 (en) | Deuterium-enriched rivastigmine | |
| FR2527210A1 (fr) | Enantiomeres d'hexahydro-2,3,3a,4,5,6 1h-indolo(3,2,1-de) (naphtyridine-1,5), leur procede de separation et leur application en therapeutique | |
| CN117480170A (zh) | 用于合成缬苯那嗪的方法 | |
| JP3001975B2 (ja) | 結晶性チアガビン塩酸塩−水和物、その製造方法および用途 | |
| JPH05286933A (ja) | アザスピロオクタン誘導体の塩 | |
| JP2019524762A (ja) | ３−ピロリジンカルボン酸誘導体の簡便な調製方法 | |
| KR20030016309A (ko) | 리그난계 화합물의 아민 염 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 DEC 2016 BY DENNEMEYER SA Effective date: 20131115 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 18 DEC 2023 BY DENNEMEYER + CO Effective date: 20140822 |
|
| EXPY | Patent expired |